by Biolexis | Sep 22, 2023 | News & Media
Biolexis Therapeutics Scientific Team participates and present their pre-clinical stage small molecule HDAC6 inhibitor program for ALS indication at the “SfN” (Society of Neuroscience) Annual Meeting to be held on Nov 11-15, 2023 – Walter E. Washington Convention... by Biolexis | Sep 22, 2023 | News & Media
Biolexis Therapeutics Scientific Team participates and present their IND stage small molecule CDK9 inhibitor program for Pancreatic Cancers indications at The “AACR-NCI-EORTC” International Conference on Molecular Targets and Cancer Therapeutics to be held on Nov... by Biolexis | Apr 13, 2023 | News & Media
July 22-24, 2023 Biolexis Therapeutics CSO invited to Chair Cancer Immunology & Immunotherapy session and present MolecuLern technology at 14th Annual World Cancer Congress – WCC 11: Cancer Immunology & Immunotherapy on July 22-24, 2023, at Barcelona, Spain.... by Biolexis | Apr 13, 2023 | News & Media
May 16-18, 2023 Biolexis CEO Dr. David J. Bearss to present MolecuLern technology at 22nd Annual Bio-IT World Conference & Expo taking place May 16-18, 2023, in Boston, MA. https://www.bio-itworldexpo.com/ by Biolexis | Apr 13, 2023 | News & Media
April 26-27, 2023 Biolexis CEO Dr. David J. Bearss to present MolecuLern technology at Ai-Driven Drug Development Summit Europe on April 26-27, 2023, in London. AI Driven Drug Development Summit Europe 2023 (aidrugdevelopmentsummiteu.com)